Stockscreener 앱 받기
0.6056
11.36%
0.0669
전일 마감가:
$0.5387
열려 있는:
$0.5438
하루 거래량:
447.17K
Relative Volume:
0.22
시가총액:
$137.84M
수익:
$175.04M
순이익/손실:
$-44.52M
주가수익비율:
-1.1346
EPS:
-0.5338
순현금흐름:
$-56.05M
1주 성능:
+5.67%
1개월 성능:
-17.05%
6개월 성능:
-42.87%
1년 성능:
-19.58%
1일 변동 폭
$0.5438
$0.6069
1주일 범위
$0.5316
$0.6078
52주 변동 폭
$0.5316
$2.05
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Company Profile
명칭
Adaptimmune Therapeutics Plc Adr
전화
44 1235 430000
주소
60 JUBILEE AVENUE, ABINGDON, OXFORDSHIRE
ADAP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ADAP
Adaptimmune Therapeutics Plc Adr
|
0.6036 | 137.84M | 175.04M | -44.52M | -56.05M | -0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.69 | 103.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.74 | 78.28B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.74 | 36.77B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.03 | 30.35B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.14 | 27.32B | 3.30B | -501.07M | 1.03B | -2.1146 |
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-30 | 개시 | H.C. Wainwright | Buy |
| 2024-05-30 | 개시 | Scotiabank | Sector Outperform |
| 2023-03-24 | 개시 | Bryan Garnier | Buy |
| 2023-01-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-11-09 | 업그레이드 | Mizuho | Neutral → Buy |
| 2021-05-28 | 개시 | Barclays | Underweight |
| 2020-04-22 | 개시 | Mizuho | Neutral |
| 2019-08-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-05-31 | 개시 | ROTH Capital | Buy |
| 2019-05-30 | 재개 | Citigroup | Buy |
| 2019-05-07 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2017-03-17 | 개시 | Wells Fargo | Market Perform |
| 2016-10-24 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2016-09-30 | 개시 | Raymond James | Outperform |
| 2016-02-25 | 개시 | Citigroup | Buy |
| 2015-06-01 | 개시 | BofA/Merrill | Neutral |
| 2015-06-01 | 개시 | Guggenheim | Buy |
| 2015-06-01 | 개시 | Leerink Partners | Outperform |
모두보기
Adaptimmune Therapeutics Plc Adr 주식(ADAP)의 최신 뉴스
AST SpaceMobile Inc Still Hasn’t Convinced Analysts? - Stocks Register
These Numbers Show Just How Powerful Standard Lithium Ltd (AMEX: SLI) Stock Is - Stocks Register
What Did We Note About Insider Trading At Lithium Americas Corp (NewCo) (NYSE: LAC)? - Stocks Register
Workhorse Group Inc (NASDAQ: WKHS) Could Pass $3.5 In One Year Stock Forecast - Stocks Register
Barnes & Noble Education Inc (NYSE: BNED) -10.53% Decline Turns Investors Away - Stocks Register
Applied Digital Corporation (NASDAQ: APLD) Could Pass $10 In One Year Stock Forecast - Stocks Register
Asana Inc (NYSE: ASAN) Up 15.57% This Year: What Is Going To Happen Next - Stocks Register
Adaptimmune's SWOT analysis: TCR-T pioneer faces challenges in stock outlook - Investing.com
Adaptimmune's SWOT analysis: TCR-T therapy pioneer faces challenges post-FDA nod - Investing.com
Royal Dutch Shell Plc ADR (SHEL-N) QuotePress Release - The Globe and Mail
Mizuho lowers Adaptimmune price target by 50%, citing pipeline shifts and cost cuts - Investing.com
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT)’s Stock Reduces -12.58%, Making It A Good Investment - Stocks Register
Analysts Predict Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) To Loss -577.97% From Current Levels. - Stocks Register
Earnings call: Adaptimmune outlines new strategy amid Tecelra launch By Investing.com - Investing.com South Africa
Adaptimmune stock holds Buy rating with lower target amid Q3 revenue outperformance - Investing.com
ADAPAdaptimmune Therapeutics plc American Depositary Shares Latest Stock News & Market Updates - StockTitan
Adaptimmune faces Nasdaq delisting over share price - Investing.com India
NVIDIA Corp (NVDA): Be Patient, You Will Learn - Stocks Register
Investing in HUYA Inc ADR (HUYA): What You Must Know - Knox Daily
Checking in on Blackstone Inc (BX) after recent insiders movement - Knox Daily
Ready to Jump After Recent Trade: Adaptimmune Therapeutics Plc ADR (ADAP) - SETE News
Ratio Examination: Adaptimmune Therapeutics Plc ADR (ADAP)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Was anything negative for Adaptimmune Therapeutics Plc ADR (ADAP) stock last session? - US Post News
Chief Commercial Officer Piccina Cintia sale 24,531 shares of Adaptimmune Therapeutics Plc ADR [ADAP] - Knox Daily
The Significance of Moving Averages in Adaptimmune Therapeutics Plc ADR Inc. (ADAP) Price Performance - The InvestChronicle
Technical analysis of Adaptimmune Therapeutics Plc ADR (ADAP) stock chart patterns - US Post News
Adaptimmune Therapeutics Plc ADR (ADAP)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
A significant driver of top-line growth: Adaptimmune Therapeutics Plc ADR (ADAP) - SETE News
Analysts review Adaptimmune Therapeutics Plc ADR’s rating - Knox Daily
How should investors view Adaptimmune Therapeutics Plc ADR (ADAP)? - US Post News
Recent Insider Activity Could Benefit Zentalis Pharmaceuticals Inc (ZNTL) - Knox Daily
Wall Street SWOT: Adaptimmune stock faces challenges despite FDA win - Investing.com
Stocks of Adaptimmune Therapeutics Plc ADR (ADAP) are poised to climb above their peers - SETE News
Insider Sale Alert: Gap, Inc. [GAP] – Is it Time to sell? - Knox Daily
Adaptimmune Therapeutics Plc ADR [ADAP] Piccina Cintia sells 24,531 Shares for $22814.0 - Knox Daily
Adaptimmune finalizes settlement with Genentech - Investing.com India
ADAP’s price-to-sales ratio: Is it a good investment opportunity? - US Post News
Ratios Uncovered: Breaking Down Adaptimmune Therapeutics Plc ADR (ADAP)’s Trailing Twelve Months Metrics - The Dwinnex
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing - Yahoo Finance UK
Adaptimmune Therapeutics Plc ADR Inc. (ADAP) Price Performance: Is It Undervalued or Overvalued? - The InvestChronicle
Recent Insider Activity Could Benefit Adaptimmune Therapeutics Plc ADR (ADAP) - Knox Daily
Zumiez Inc’s latest rating changes from various analysts - Knox Daily
AdaptHealth Stock Earns RS Rating Upgrade - MSN
A new trading data show Adaptimmune Therapeutics Plc ADR (ADAP) is showing positive returns. - SETE News
Predicting Adaptimmune Therapeutics Plc ADR’s (ADAP) earnings for the current quarter - US Post News
Director SIMON WILLIAM E JR acquire 45,000 shares of Douglas Emmett Inc [DEI] - Knox Daily
Buying Buzz: Noble Corp Plc [NE] 10% Owner APMH Invest A/S purchases 324,984 shares of the company - Knox Daily
There is no doubt that Adaptimmune Therapeutics Plc ADR (ADAP) ticks all the boxes. - SETE News
Analyzing Ratios: Adaptimmune Therapeutics Plc ADR (ADAP)’s Financial Story Unveiled - The Dwinnex
Adaptimmune Therapeutics Plc ADR (ADAP) stock analysis: A simple moving average approach - US Post News
A company insider recently sold 24,531 shares of Adaptimmune Therapeutics Plc ADR [ADAP]. Should You Sale? - Knox Daily
Adaptimmune Therapeutics Plc Adr (ADAP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Adaptimmune Therapeutics Plc Adr 주식 (ADAP) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Rawcliffe Adrian | Chief Executive Officer |
Jan 17 '24 |
Sale |
0.67 |
30,080 |
20,244 |
44,848 |
| Rawcliffe Adrian | Chief Executive Officer |
Jan 16 '24 |
Sale |
0.79 |
9,304 |
7,350 |
14,104 |
| Norry Elliot | Chief Medical Officer |
Jan 17 '24 |
Sale |
0.67 |
18,276 |
12,300 |
7,785 |
| Norry Elliot | Chief Medical Officer |
Jan 16 '24 |
Sale |
0.79 |
2,287 |
1,807 |
3,363 |
| Lunger John | Chief Patient Supply Officer |
Jan 17 '24 |
Sale |
0.67 |
18,114 |
12,191 |
7,785 |
| Lunger John | Chief Patient Supply Officer |
Jan 16 '24 |
Sale |
0.79 |
4,681 |
3,698 |
7,023 |
| Bertrand William C JR | Chief Operating Officer |
Jan 17 '24 |
Sale |
0.67 |
18,908 |
12,725 |
7,785 |
| Bertrand William C JR | Chief Operating Officer |
Jan 16 '24 |
Sale |
0.79 |
4,681 |
3,698 |
7,023 |
| Norry Elliot | Chief Medical Officer |
Jan 12 '24 |
Sale |
0.85 |
7,799 |
6,661 |
11,841 |
| Norry Elliot | Chief Medical Officer |
Jan 11 '24 |
Sale |
0.84 |
4,009 |
3,354 |
6,104 |
1.01%
자본화:
|
볼륨(24시간):